Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer

A study was undertaken to determine the maximum tolerated dose, the dose-limiting toxicities, and the response rate of irinotecan administered weekly with concurrent thoracic radiation therapy in patients with locally advanced non-small-cell lung cancer. In a phase I/II clinical trial, patients with...

Descripción completa

Detalles Bibliográficos
Autores principales: Takeda, K, Negoro, S, Kudoh, S, Okishio, K, Masuda, N, Takada, M, Tanaka, M, Nakajima, T, Tada, T, Fukuoka, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 1999
Materias:
Regular Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362741/
https://www.ncbi.nlm.nih.gov/pubmed/10188891
http://dx.doi.org/10.1038/sj.bjc.6690233

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2362741/
https://www.ncbi.nlm.nih.gov/pubmed/10188891
http://dx.doi.org/10.1038/sj.bjc.6690233

Ejemplares similares